- Home
- FGF vs ALGS Comparison
FGF vs ALGS Comparison
Compare FGF & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- ALGS
- Stock Information
- Founded
- FGF 2012
- ALGS 2018
- Country
- FGF United States
- ALGS United States
- Employees
- FGF N/A
- ALGS N/A
- Industry
- FGF Property-Casualty Insurers
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- ALGS Health Care
- Exchange
- FGF Nasdaq
- ALGS Nasdaq
- Market Cap
- FGF 20.9M
- ALGS 50.4M
- IPO Year
- FGF N/A
- ALGS 2020
- Fundamental
- Price
- FGF $16.41
- ALGS $7.31
- Analyst Decision
- FGF
- ALGS Strong Buy
- Analyst Count
- FGF 0
- ALGS 1
- Target Price
- FGF N/A
- ALGS $70.00
- AVG Volume (30 Days)
- FGF 4.9K
- ALGS 126.9K
- Earning Date
- FGF 08-13-2025
- ALGS 08-05-2025
- Dividend Yield
- FGF N/A
- ALGS N/A
- EPS Growth
- FGF N/A
- ALGS N/A
- EPS
- FGF N/A
- ALGS N/A
- Revenue
- FGF $13,260,000.00
- ALGS $3,270,000.00
- Revenue This Year
- FGF N/A
- ALGS N/A
- Revenue Next Year
- FGF N/A
- ALGS $51.55
- P/E Ratio
- FGF N/A
- ALGS N/A
- Revenue Growth
- FGF N/A
- ALGS N/A
- 52 Week Low
- FGF $14.21
- ALGS $3.76
- 52 Week High
- FGF $38.40
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- FGF 43.77
- ALGS 52.31
- Support Level
- FGF $15.93
- ALGS $6.82
- Resistance Level
- FGF $17.98
- ALGS $8.66
- Average True Range (ATR)
- FGF 0.49
- ALGS 0.76
- MACD
- FGF -0.13
- ALGS -0.09
- Stochastic Oscillator
- FGF 16.38
- ALGS 26.54
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.